// App-Quantinova.ai

OP0115 : EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL

Researchers

Presenter

  • E. Matteson

Principal Investigators

  • C. Kelly

  • J. Distler

  • A. M. Hoffmann-Vold

  • J. Seibold

  • S. Mittoo

  • O. Distler

  • P. F. Dellaripa

  • A. James

  • R. Schlenker-Herceg

  • S. Stowasser

  • M. Quaresma

  • K. R. Flaherty

Medical Centers

  • Mayo Clinic College of Medicine and Science, Urology, Rochester, United States of America

  • Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Scleroderma Research Consultants LLC, Aiken, South Carolina, United States of America

  • Universtiy Health Network, Toronto, ON, Canada

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

  • Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, United States of America

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States.

  • Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, United States of America

Locations

  • United States

  • United Kingdom

  • Germany

  • Norway

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Interstitial lung disease

  • Pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved